NCT05515601View on ClinicalTrials.gov

A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

396

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

February 20, 2023

Study Completion Date

February 20, 2023

Conditions
Healthy
Interventions
DRUG

Mirikizumab

Administered SC.

Trial Locations (6)

32117

LabCorp CRU, Inc., Daytona Beach

53704

LabCorp CRU, Inc., Madison

56529

Axis, Dilworth

65802

QPS, Springfield

75247

Labcorp Clinical Research LP, Dallas

90630

Altasciences Clinical Los Angeles, Inc, Cypress

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY